Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer

13 Jun 2024

Abstract excerpt

• Arsenic trioxide (ATO) was recently shown to reactivate mutant p53 and restore wild-type functionality. • ATO was a more potent inhibitor of the proliferation of mutant p53 cell lines than wild-type p53 cell lines. • Triple-negative breast cancer (TNBC) cell lines were more sensitive to ATO than non-TNBC cell lines. • ATO induced wild-type p53 canonical target genes such as CDKN1A, SLC7A11, HMOX1, BBC3, PMAIP1,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Estrogen and related hormone effects
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38870678
DOI: 10.1016/j.tranon.2024.102025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancerPMID 38870678Read ↗

Inhibition of GPX4 Induces the Death of p53-Mutant Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivoSemantic proximity Read ↗

Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.Semantic proximity Read ↗

Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.Semantic proximity Read ↗

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.Semantic proximity Read ↗

Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic StrategiesSemantic proximity Read ↗

Inhibition of GPX4 Induces the Death of p53-Mutant Triple-Negative Breast CancerSemantic proximity Read ↗

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer CellsSemantic proximity Read ↗

TP53R175H mutation promotes breast cancer cell proliferation through CORO1A-P38 MAPK pathway regulation.Semantic proximity Read ↗

Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.Semantic proximity Read ↗

Molecular Targets of Arsenic Trioxide in Malignant CellsSemantic proximity Read ↗

AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell SelectivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.